414 filings
8-K
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
10-Q
2024 Q1
COCP
Cocrystal Pharma Inc
Quarterly report
13 May 24
8:00am
DEF 14A
COCP
Cocrystal Pharma Inc
Definitive proxy
7 May 24
4:30pm
8-K
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
PRE 14A
COCP
Cocrystal Pharma Inc
Preliminary proxy
26 Apr 24
5:12pm
8-K
zbd6t4rku
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
yo0ubv4p j489act
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
hiouh
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
juv2qu9ejy
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
eny5xyuft99 hc54
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
ugr116
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
9vrpb
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
ln39wmnp5hgtiwx
4 Dec 23
Regulation FD Disclosure
8:00am
8-K
70gtdx6r9n yzdi2vk
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
yw0c qowfwld
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
8ubkxjjo ovltujwia8e
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
k9rgdzou2wfj9vms8y
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm